Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients

World Journal of Gastroenterology

Volumn 18, Issue 1, 2012, Pages 55-63

  Aljumah, Abdulrahman A ^a   Saeed, Mohamed A ^a   Al Flaiw, Ahmed I ^a   Al Traif, Ibrahim H ^a   Al Alwan, Abduljaleel M ^a   Al Qurashi, Salem H ^a   Al Ghamdi, Ghormallah A ^a   Al Hejaili, Fayez F ^a   Al Balwi, Mohammed A ^b   Al Sayyari, Abdulla A ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

Author keywords

Allograft rejection; Hepatitis c; Pegylated interferon; Renal transplant; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER FUNCTION; MALE; NONHUMAN; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84855529607     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i1.55     Document Type: Article

References (69)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567
2. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455
3. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Anwar W, Strickland GT, Fix AD, Sallam I. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositiv-ity. Hepatology 2001; 33: 248-253
4. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-583
5. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999
6. Morales MF, Lossi JS, Alderete TN, Noli D. Prevalence and seroconversion to HCV in hemodialyzed patients, and epidemiological factors. Transplant Proc 1996; 28: 3402-3405
7. Pujol FH, Ponce JG, Lema MG, Capriles F, Devesa M, Sirit F, Salazar M, Vásquez G, Monsalve F, Blitz-Dorfman L. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol 1996; 34: 1633-1636
8. Geerlings W, Tufveson G, Ehrich JH, Jones EH, Landais P, Loirat C, Mallick NP, Margreiter R, Raine AE, Salmela K. Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1994; 9 Suppl 1: 6-25
9. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-2022
10. Lin DY, Lin HH, Huang CC, Liaw YF. High incidence of hepatitis C virus infection in hemodialysis patients in Taiwan. Am J Kidney Dis 1993; 21: 288-291
11. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gil-lespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-2342
12. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805
13. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670
14. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476
15. Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55: 273-276
16. Chan TM, Lok AS, Cheng IK, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993; 104: 862-868
17. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-861
18. Ponz E, Campistol JM, Barrera JM, Gil C, Pinto J, Andreu J, Bruguera M. Hepatitis C virus antibodies in patients on he-modialysis and after kidney transplantation. Transplant Proc 1991; 23: 1371-1372
19. Renal transplantation in patients with hepatitis C virus antibody. A long national experience. NDT Plus 2010; 3: 241-246
20. Ynares C, Johnson HK, Kerlin T, Crowe D, MacDonell R, Richie R. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival--a 5- and 10-year follow-up. Transplant Proc 1993; 25: 1466-1468
21. Mitwalli AH, Alam A, Al-Wakeel J, Al Suwaida K, Tarif N, Schaar TA, Al Adbha B, Hammad D. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 2006; 102: c72-c80
22. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Bréchot C, Pol S. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17:129-133
23. Perez RM, Ferreira AS, Medina-Pestana JO, Cendoroglo-Ne-to M, Lanzoni VP, Silva AE, Ferraz ML. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol 2006; 40: 444-448
24. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing Ho Y, Neng Lai K, Mao Chan T. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-878
25. Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fbrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254-1258
26. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-683
27. Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-78
28. Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26: 2075
29. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-628
30. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070
31. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant inter-feron alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431
32. Ozgür O, Boyacioǧlu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-2106
33. Durlik M, Gaciong Z, Rowińska D, Rancewicz Z, Lewan-dowska D, Kozłowska B, Wyzgał J, Soluch L, Walewska-Zi-elecka B, Rowiński W, Lao M. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11 Suppl 1: S135-S139
34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
35. Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, Denk H, Desmet V, Korb G, MacSweeni R, James Phillips M, Portmannl B, Paulsen H, Scheuer P, Schmid M and Thaler H. Histological grading and staging of chronic hepatitis. J Hepa-tol 1995; 22: 696-699
36. Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-858
37. Seth AK, Anand AC, Gedela SR, Varma PP, Baliga KV. Rapid progression of hepatitis C-induced liver failure in renal allograft recipients. Indian J Gastroenterol 2006; 25: 155-156
38. Al-Faleh FZ, Aljumah A, Rezeig M, Al-Kanawi M, Alahdal M, Al-Humayed S, Mayet I, Al-Juhani M, Al-Karawi M, George K, Sbeih F. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 2000; 7: 287-291
39. Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004; 25: 1935-1938
40. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiff-man M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
41. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
42. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
43. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sil-likens P, Weiland O. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-598
44. Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, Heilman RL, Rakela J, Mekeel K, Reddy K, Vargas HE. Treatment of hepatitis C in renal transplantation candidates: a single-center experience. Transplantation 2010; 90: 407-411
45. Alsaran K, Sabry A, Shaheen N. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience. Int Urol Nephrol 2011; 43: 865-873
46. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-1834
47. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098
48. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodi-alysis patients with chronic hepatitis C: study of tolerance, effcacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-c139
49. Kim E, Ko HH, Yoshida EM. Treatment issues surrounding hepatitis C in renal transplantation: a review. Ann Hepatol 2011; 10: 5-14
50. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-321
51. Ayaz C, Celen MK, Yuce UN, Geyik MF. Effcacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008; 14: 255-259
52. Aljumah AA, Cattral MS, Greig PD, Wanless IR, Krajden M, Hemming AW, Lilly LB, Levy GA. Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplant Proc 1997; 29: 514
53. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29: 783
54. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192
55. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, Lebray P, Sobesky R, Serpaggi J, Kreis H, Pol S. Histopathologic effcacy of ribavirin mono-therapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-857
56. Kamar N, Izopet J, Alric L, Rostaing L. Lack of evidence for ribavirin monotherapy effcacy on liver fbrosis in hepatitis C virus positive renal transplant patients. Transplantation 2005; 79: 1770-1771; author reply 1771
57. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413-1422
58. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colle-dan M, Strazzabosco M. Treatment with pegylated inter-feron and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41: 216-220
59. Mukherjee S, Ariyarantha K. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin. Transplantation 2007; 84: 1374-1375
60. Pageaux GP, Hilleret MN, Garrigues V, Bismuth M, Audin-Mamlouk H, Zarski JP, Mourad G. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int 2009; 22: 562-567
61. Rhodes J, Jones DH, Bleehen NM. Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo. Clin Exp Immunol 1983; 53: 739-743
62. Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, Magee JC, Sung RS. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008; 85: 1601-1606
63. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68-73
64. Knight SR, Russell NK, Barcena L, Morris PJ. Mycopheno-late mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009; 87: 785-794
65. Martin P, Mitra S, Farrington K, Martin NE, Modi MW. Pegylated (40 KDA) interferon alfa-2a is unaffected by renal impairment [Abstract]. Hepatology 2000; 32: 370
66. Modi MW, Fulton JS, Buckman DK, Wright TL, Moore DJ. Clearance of pegylated (40 kDa) interferon alfa-2a Pegasys is primarily hepatic [Abstract]. Hepatology 2000; 32: 371
67. Lamb M, Marks IM, Wynohradnyk L, Modi MW, Preston RA, Pappas SC. Peginterferon alfa-2a, 40 kDa Pegasys can be administered safely in patients with end stage renal disease [Abstract]. Hepatology 2001; 34: 326
68. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109-1115
69. Heydtmann M, Freshwater D, Dudley T, Lai V, Palmer S, Hübscher S, Mutimer D. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fbrosis following liver transplantation. Am J Transplant 2006; 6: 825-833